Clinical Trials
Alpine is committed to bringing innovative new drug therapies to patients with serious or life-threatening diseases or conditions.
Povetacicept (ALPN-303)
PHASE 1
A Study of Povetacicept in Adult Healthy Volunteers
The goal of this study was to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of povetacicept.
PHASE 1b
An Open-Label Study of Povetacicept (ALPN-303) in Autoimmune Kidney Diseases
The goal of this open-label clinical study is to evaluate multiple dose levels of povetacicept (ALPN-303) in adults with autoimmune kidney disease to determine if povetacicept is safe and potentially beneficial in treating these diseases.
STUDY NUMBER
NCT05732402
INDICATION(S)
Immunoglobulin A (IgA) Nephropathy, Primary Membranous Nephropathy, or Lupus-Related Kidney Disease (Lupus Nephritis)
PHASE 1b
An Open-label Study of Povetacicept (ALPN-303) in Subjects With Autoimmune Cytopenias
The goal of this clinical study is to evaluate povetacicept (ALPN-303) in adults with autoimmune cytopenias of immune thrombocytopenia, autoimmune hemolytic anemia, and cold agglutinin disease to determine if povetacicept is safe and potentially beneficial in treating these diseases.
STUDY NUMBER
NCT05757570
INDICATION(S)
Immune Thrombocytopenia, Idiopathic Thrombocytopenic Purpura, Warm Autoimmune Hemolytic Anemia, Cold Agglutinin Disease
Related Materials
Learn more about the povetacicept studies from recent presentations at scientific conferences and manuscript publications.
Acazicolcept (ALPN-101)
PHASE 2
A Randomized, Double-Blind, Placebo-Controlled Study of ALPN-101 in Systemic Lupus Erythematosus
The goal of this multinational, randomized, blinded study is to evaluate the safety, tolerability, efficacy, immunogenicity, pharmacokinetics, and pharmacodynamics of acazicolcept (ALPN-101) in adults with moderate to severe active systemic lupus erythematosus (SLE).
Related Materials
Learn more about the acazicolcept studies from the 2019 ASH Annual Meeting and 2020 EULAR E-Congress.
Expanded Access
Alpine is committed to bringing innovative new drug therapies to patients with serious or life-threatening diseases or conditions. Participation in a clinical trial is currently the most appropriate way to access our investigational therapies.
In line with the 21st Century Cures Act (Pub.L. 114-255), Alpine may revise this policy at any time.
Additional Resources
- Learn about the FDA’s position on expanded access
- Find out more about Alpine’s clinical trials
- Search enrolling clinical trials for a specific medicine or disease at ClinicalTrials.gov
Join us in the discovery and development of next-generation immunotherapies.
Current job openingsLearn more about Alpine
